Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 15 November 2019, 02:00 HKT/SGT

Source: Singapore eDevelopment Ltd
Global BioLife to Present 3F Antimicrobial Fragrance at 2020 ASM Biothreats
A New Method to Prevent and Treat Tuberculosis

SINGAPORE, Nov 15, 2019 - (ACN Newswire) - Global BioLife Inc, the U.S. subsidiary of Singapore eDevelopment Ltd (SeD), will present its 3F Antimicrobial Fragrance as a new method to prevent and treat Tuberculosis at the ASM Biothreats Conference, 28 to 30 January, 2020 in Arlington, Virginia. ASM Biothreats is a one-of-a-kind program that explores emerging industry technologies and offers biodefense, biosecurity and biological threats professionals the opportunity to exchange knowledge and ideas that will shape the future of this emerging field.

Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis (Mtb) bacteria. TB primarily affects the lungs, is transmitted through the open air when an infected person sneezes, coughs, talks, or laughs. Symptoms of TB include a low-grade fever, night sweats, weakness or tiredness, and weight loss. TB kills someone approximately every 18 seconds, causing over 1.6 million deaths in 2017 alone. According to the WHO, one-quarter of the world's population has latent TB, which means people have been infected by TB bacteria, making it the top infectious killer in the world.

In 2017, Global BioLife and US-based Chemia Corporation, a provider of high quality, cost effective fragrances for personal care, household and industrial products, began collaboration to develop a suite of fragrances labeled 'Functional Fragrance Formulation' or 3F, which could go towards fighting disease rather than simply smelling pleasant. "The impact of functional fragrances will transform the modern perfume industry," said Mr. Thomas A. Meyer, Chemia's Vice-President of Innovation and Sustainability.

The 3F Antimicrobial Fragrance was shown to inhibit Mycobacterium tuberculosis (Mtb), the causative bacterial agent of tuberculosis, in experiments performed by ATCC in its High Containment Laboratory under BioSafety Level 3 conditions. ATCC designs custom services for testing the world's most dangerous viruses and bacteria, and has expertise in handling and experimenting on dangerous pathogens such as Mtb.

Mr. Daryl Thompson, Global BioLife's Director of Scientific Initiatives, and a Nobel Prize nominee in 2015 and 2016 for his research on pandemic technology, leads research on the 3F project. "3F works by taking advantage and exploiting the sophisticated bacterial or viral communication system called quorum sensing. In essence, we can utilise quorum sensing to instruct the bacterial or viral agent to shut down or stop replication.

"The 3F project was designed to provide a solution for open environment defense strategies, to prevent or suppress the transmission of aerosoled viral and bacterial particles that cause the spread of influenza, MRSA and tuberculosis in congested areas. The process has been demonstrated to be very effective," says Thompson. "3F is a new paradigm, designed to provide solutions for emerging epidemics and pandemics globally using cutting edge methods."

"As a leading developer of authenticated cells lines and microorganisms, ATCC was honored to provide Global BioLife with custom susceptibility testing to determine if their product was able to kill MTB," said Dr. Manzour Hazbon, ATCC Senior Scientist. "This fragrance is effective even in low concentrations, and an excellent candidate to treat tuberculosis, particularly important as there are few antibiotics effective in treating antibiotic-resistant tuberculosis cases."

Dr. Roscoe M. Moore Jr, former Senior Assistant U.S. Surgeon General and Epidemic Intelligence Officer at U.S. Center for Disease Control and Prevention, serves as Senior Scientific Adviser to Global BioLife. "I'm excited about the results 3F has demonstrated, and 3F's potential to address a global epidemic by providing safe and versatile protection layers. There is a strong need for new and effective measures to address the spread of TB globally. Global BioLife's solution will help save lives on a global scale."

"It is an honor to be invited to present our groundbreaking research at the 2020 ASM Biothreat Conference," said the Executive Chairman of SeD, Mr Chan Heng Fai. "We are excited about this potential breakthrough in the 3F Series. Global BioLife will step up in its efforts to provide real solutions for global healthcare problems."

About Global BioLife Inc.
Global BioLife Inc., a U.S. subsidiary of Singapore eDevelopment Ltd, is involved in drug discovery and development for the prevention, inhibition and treatment of neurological, oncology and immuno-related diseases. Global BioLife is also collaborating with Chemia to develop mosquito defense technologies (DEET-free) to protect against diseases such as Zika and Dengue. For more information, visit:

About Singapore eDevelopment Ltd (SeD)
Singapore eDevelopment Ltd (SGX:40V), Incorporated on 9 Sep 2009 and listed on the SGX in July 2010, is involved in property in the US and W Australia, IT-related businesses, biomedical products, and investment activities. For more information, please visit: or email [email protected].

Nov 15, 2019 02:00 HKT/SGT
Topic: Clinical Trial Results
Sectors: BioTech, HealthCare, Cosmetics/Spec.Chem
From the Asia Corporate News Network

Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Singapore eDevelopment Ltd
July 31, 2020 15:00 HKT/SGT
Impact Biomedical initiates Quantum, a new frontier in Pharmaceutical Development
June 24, 2020 14:00 HKT/SGT
Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance
June 17, 2020 18:00 HKT/SGT
Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal
June 1, 2020 13:00 HKT/SGT
Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts
Apr 24, 2020 10:00 HKT/SGT
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts
Mar 18, 2020 11:00 HKT/SGT
Impact BioMedical's Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the COVID-19 outbreak
Oct 29, 2019 09:00 HKT/SGT
Global BioLife to present Functional Fragrance Formula at the American Society for Microbiology's Biothreats Conference as a New Method to Prevent and Treat Tuberculosis
July 24, 2019 15:00 HKT/SGT
Global BioLife unveils naturally modified Laetose at Harvard Global Catalyst Health Summit
June 12, 2019 14:00 HKT/SGT
Global BioLife's 3F Mosquito Repellent Formula performs well in Independent Testing
Jan 28, 2019 12:00 HKT/SGT
Global BioLife's 3F Antimicrobial Fragrance shows Efficacy against Tuberculosis
More news >>
 News Alerts
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: